Moderna’s mFlusiva is the seasonal influenza shot that replaces the traditional egg-grown or cell-grown virus protein with a messenger RNA instruction, and the Food and Drug Administration has licensed it for individuals 50 years of age and older. Coverage of the licensing calls it the first mRNA influenza vaccine in the United States, a status that follows from the technology.
The age line is the practical part. Adults 65 and older gain a further alternative alongside the high-dose and adjuvanted products already on the shelf, and the rules for each age band differ in the type of approval behind them.
BLA 125869 and the FDA’s Wording
The FDA’s own MFLUSIVA page lists ModernaTX, Inc. as the applicant, identifies the file as biologics license application 125869/0, and gives August 5, 2026 as the approval date. Its indication reads that MFLUSIVA is “a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B” in individuals 50 years of age and older. That sentence is the license; everything else in the coverage is interpretation of it.
Dates in news copy do not all match. Station copy carried by outlets such as Hawaii News Now and the trade site pharmaphorum is dated August 6, a day after the FDA listing, while a September 30 broadcast story from KNOE describes the same vaccine as cleared ahead of the flu season. Those later dates reflect when stories ran, and the agency’s own page carries the earlier one. Where the sources disagree on the day, the FDA listing governs, and it is also the only one of these documents that names the sponsor in the agency’s own words.
Messenger RNA Instead of Viral Protein
KNOE quotes Kawsar Talaat of the Johns Hopkins Bloomberg School of Public Health explaining the idea: the vaccine lets cells make some of the influenza proteins, which in turn produces an immune response to the virus. Instead of injecting a prepared piece of the virus, the shot delivers genetic instructions, and the body’s own cells build the protein that the immune system then learns to recognize.
KNOE’s report describes mFlusiva as the nation’s first and only seasonal influenza vaccine using mRNA technology, and says it gives people 65 and older an additional option beside high-dose and adjuvanted vaccines. The FDA emphasized, per that report, that annual vaccination remains the most effective defense against severe complications and hospitalization.
Full Approval at 50 to 64, Accelerated at 65 and Over
The age band is not treated uniformly. Per the Hawaii News Now report, adults 50 to 64 received full approval, backed by a study of 40,000 people in which the new shot produced “27% fewer flu cases” than a different common flu vaccine brand. For those 65 and older, approval came under the accelerated pathway, resting on a smaller study showing a strong immune response compared with an existing high-dose senior vaccine. pharmaphorum adds that a confirmatory trial is required for the older group. In plain terms, the 50-to-64 label rests on cases of flu actually prevented, while the 65-and-older label rests on antibody response used as a stand-in until that follow-up trial reports. The FDA’s own page lists a single indication of 50 years and older, so the split is visible in the news accounts of the approval rather than in the indication sentence.
The path to licensing was unusually bumpy, and the sequence is worth laying out in order. The same coverage describes a public dispute in which an FDA official initially blocked the application, and the agency reversed course after Moderna challenged the decision. pharmaphorum quotes the company saying the regulator “was deviating from already agreed-upon parameters for the filing,” over concerns about the comparator vaccine dose in the trial. An independent FDA advisory panel recommended approval in June, according to Hawaii News Now, and the vaccine’s reactions, including injection-site pain, fever, headache, fatigue and muscle aches, were reported as occurring somewhat more often than with today’s flu shots, with no major safety concerns identified.
Other Flu Shots Still on the Menu
An mRNA vaccine is one option in a crowded field. KNOE lists standard-dose and cell-based shots for ages six months and up, recombinant vaccines from age nine, and the FluMist nasal spray for ages two to 49, excluding pregnant women and the immunocompromised. The Centers for Disease Control and Prevention still advises that everyone six months and older get a flu vaccine every season, with rare exceptions.
Timing follows the usual calendar. Flu activity typically climbs in October and peaks between December and February, according to KNOE, and pharmaphorum reported that commercial availability was expected within weeks of licensing for the 2026-2027 season. The comparison data that stands out is the 27 percent reduction in flu cases among 50- to 64-year-olds in the 40,000-person study.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- Invisible volcanic gas at a California ski resort has killed three ski patrollers
- Verizon just moved to cut landline phone service in 9 states within weeks
- Tropical Storm Rachel is dumping up to 12 inches on four Mexican states on its way to major hurricane strength
- The NSA is again telling phone owners to switch off one location setting
